Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Assets (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Current Assets for 6 consecutive years, with $388.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets changed N/A year-over-year to $388.5 million, compared with a TTM value of $388.5 million through Sep 2025, changed N/A, and an annual FY2024 reading of $396.4 million, up 1.12% over the prior year.
  • Current Assets was $388.5 million for Q3 2025 at Cytek Biosciences, up from $380.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $454.0 million in Q4 2022 and bottomed at $216.9 million in Q2 2021.
  • Average Current Assets over 5 years is $404.3 million, with a median of $425.2 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 106.95% in 2021, then fell 13.65% in 2023.
  • Year by year, Current Assets stood at $431.7 million in 2021, then increased by 5.16% to $454.0 million in 2022, then fell by 13.65% to $392.1 million in 2023, then increased by 1.12% to $396.4 million in 2024, then decreased by 2.01% to $388.5 million in 2025.
  • Business Quant data shows Current Assets for CTKB at $388.5 million in Q3 2025, $380.5 million in Q1 2025, and $396.4 million in Q4 2024.